Home›The Library›Efpeglenatide
Efpeglenatide
Efpeglenatide is a once-weekly GLP-1 receptor agonist with a genuinely unusual business story layered on top of real trial evidence: Sanofi walked away from ever launching it in December 2019, before its own pivotal cardiovascular-outcomes trial had even reported — and that trial then found a real, statistically significant 27% reduction in major cardiovascular events. Sanofi returned the drug's rights to its original developer, Hanmi Pharmaceutical, in 2020; as of this review Hanmi is pursuing a South Korean approval for an obesity indication, with no US or EU filing pending.
On this page
In brief
Should you care? Relevant as a genuinely different kind of case study from this site's other still-investigational GLP-1-family pages (survodutide, retatrutide) — efpeglenatide already has a completed, published, positive Phase 3 cardiovascular-outcomes trial behind it, and was abandoned by its original commercial sponsor for reasons that had nothing to do with that trial's result.The short version
- What it is: an exendin-4 (the same parent molecule as exenatide) based GLP-1 receptor agonist, fused via Hanmi's LAPSCOVERY platform to a modified antibody Fc fragment for extended, once-weekly half-life — the same general Fc-fusion approach as dulaglutide, built by a different company.
- AMPLITUDE-O (4,076 patients): a real, published, randomized, placebo-controlled cardiovascular-outcomes trial found a 27% relative reduction in major cardiovascular events (7.0% vs. 9.2%) and a 32% reduction in a composite kidney-function outcome.
- The twist: Sanofi announced in December 2019 — over a year and a half before AMPLITUDE-O's results were known — that it would exit diabetes and cardiovascular R&D and never launch efpeglenatide at all, later returning the rights to Hanmi Pharmaceutical, its original developer.
An exendin-4-based GLP-1 agonist built for once-weekly dosing
Efpeglenatide is built on exendin-4, the same lizard-venom-derived peptide that is the parent molecule of this site's exenatide page, rather than on native human GLP-1 itself. South Korea's Hanmi Pharmaceutical extended exendin-4's short natural half-life using its own LAPSCOVERY ("Long Acting Protein/Peptide dISCOVERY") platform, part of what Hanmi calls its "Quantum Project" portfolio: the exendin-4 peptide is joined through a non-covalent, non-peptide linker to a modified IgG4 antibody Fc fragment, extending circulating half-life enough to support once-weekly subcutaneous injection. That's the same broad engineering strategy — fusing a GLP-1-family peptide to an antibody Fc domain rather than modifying the peptide's own fatty-acid chemistry — that this site's dulaglutide page describes for a chemically unrelated molecule from a different company, giving efpeglenatide a genuine point of mechanistic comparison already covered here.
Sanofi licenses it, then walks away before the data is in
Sanofi licensed worldwide rights to efpeglenatide from Hanmi in November 2015, as part of a broader "Quantum Project" agreement covering a portfolio of long-acting diabetes candidates — efpeglenatide, a once-weekly basal insulin, and a fixed-dose weekly GLP-1/insulin combination — for a reported €400 million upfront payment plus up to €3.5 billion in development, regulatory and sales milestones. Sanofi took efpeglenatide through the remainder of its Phase 3 program, including the cardiovascular-outcomes trial described below.
A strategic exit, not a trial failure
In December 2019, roughly 100 days into his tenure, incoming Sanofi CEO Paul Hudson announced a company-wide R&D strategy overhaul: Sanofi would stop research and development in diabetes and cardiovascular disease entirely — retaining its existing insulin business but abandoning new candidates in both areas — to concentrate resources on immunology, oncology and vaccines. As part of that announcement, Sanofi stated it would not launch efpeglenatide itself and would instead seek a partner to commercialize it. In May 2020, Sanofi notified Hanmi of its intent to return the drug's rights outright, and the two companies formalized the return in June 2020 — a decision driven by Sanofi's own corporate strategy, made more than a year before AMPLITUDE-O, efpeglenatide's own pivotal cardiovascular trial, had reported any results at all.
AMPLITUDE-O: the trial that reported after the company had already left
AMPLITUDE-O (Gerstein HC, Sattar N, Rosenstock J, et al., for the AMPLITUDE-O Trial Investigators, "Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes," N Engl J Med 2021;385(10):896-907, PMID 34215025, DOI 10.1056/NEJMoa2108269) randomized 4,076 adults with type 2 diabetes and established cardiovascular or kidney disease to once-weekly efpeglenatide (4mg or 6mg) or placebo, added to standard care, with a median follow-up of 1.81 years. The primary composite outcome — major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction or nonfatal stroke) — occurred in 7.0% of the efpeglenatide group versus 9.2% of the placebo group, a 27% relative risk reduction that met statistical significance for both superiority and the trial's pre-specified noninferiority margin. A secondary composite renal outcome (a substantial decline in kidney function, new macroalbuminuria, or related endpoints) occurred in 13.0% of the efpeglenatide group versus 18.4% of the placebo group, a 32% relative reduction. Because the trial had already been underway when Sanofi returned the drug's rights, its results reported more than a year after the company that ran it had already decided never to bring the drug to market — a genuinely unusual sequence among the drugs this site covers, where a positive, published, peer-reviewed Phase 3 outcomes trial arrived after, not before, its sponsor's exit.
Hanmi's second act: from an abandoned diabetes drug to a Korean obesity filing
After regaining the rights in mid-2020, Hanmi initially sought a new commercial partner for efpeglenatide in its original type 2 diabetes cardiovascular-risk indication without success. In July 2023, Hanmi announced it would reposition the molecule for a different indication entirely — obesity — in the Korean market specifically, submitting an Investigational New Drug application to Korea's Ministry of Food and Drug Safety (MFDS) on 28 July 2023 for a Phase 3 trial. That repositioning has continued: Hanmi completed a regulatory application to the MFDS for an obesity indication on 17 December 2025, and a separate Phase 3 IND covering efpeglenatide in combination with SGLT-2 inhibitors and metformin for a type 2 diabetes indication was approved on 21 January 2026. As of this review, Hanmi has stated a target of obesity approval in South Korea in the second half of 2026, with an additional diabetes-combination indication targeted for 2028 — timelines that, like any company-stated regulatory target, are worth checking against a current source rather than assumed to have already happened.
Current status
Efpeglenatide remains unapproved in the US, the EU, and every market outside the pending South Korean review as of this review. The obesity-indication Phase 3 trial behind that pending filing reported its core results in October 2025: 448 adults with obesity but without diabetes lost a mean 9.75% of body weight at 40 weeks on efpeglenatide, against a negligible change on placebo. No US or EU regulatory filing is pending. Hanmi retains full global rights following Sanofi's 2020 exit and has not announced a new ex-Korea commercial partner; whether efpeglenatide reaches Western markets likely depends on Hanmi first securing the Korean obesity approval it is currently pursuing, then finding a partner willing to run the additional trials a US or EU filing would require on top of the AMPLITUDE-O data already in hand.
References
- Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, Lam CSP, Khurmi NS, Heenan L, Del Prato S, Dyal L, Branch K, for the AMPLITUDE-O Trial Investigators, "Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes," N Engl J Med 2021;385(10):896-907, PMID 34215025, DOI: 10.1056/NEJMoa2108269.
- Sanofi and Hanmi Pharmaceutical license agreement for efpeglenatide and a portfolio of long-acting diabetes candidates, announced 5 November 2015 (Sanofi and Hanmi press releases; Fierce Biotech, Fierce Pharma contemporaneous coverage).
- Sanofi CEO Paul Hudson's R&D strategy announcement discontinuing diabetes and cardiovascular research and declining to launch efpeglenatide, December 2019 (BioPharma Dive, Fierce Pharma, Pharmaphorum, C&EN contemporaneous coverage); Sanofi notice of intent to return efpeglenatide rights to Hanmi, May 2020, formalized June 2020 (Korea Biomed, BioWorld contemporaneous coverage).
- Hanmi Pharmaceutical announcement repositioning efpeglenatide for an obesity indication and Investigational New Drug application to Korea's Ministry of Food and Drug Safety, 28 July 2023 (PR Newswire; KED Global); Hanmi Phase 3 core obesity-trial results (448 adults, 9.75% mean weight loss at 40 weeks vs. placebo), reported October 2025; Hanmi regulatory application for the obesity indication (development code HM11260C) completed 17 December 2025, and Phase 3 IND for a combination diabetes indication approved 21 January 2026 (Korea Biomed, KED Global, TheBioNews contemporaneous coverage).